Axcella Health — Technical Presentation (May 2020)
23 slides from Axcella Health's technical presentation, May 6, 2020
Slide 1: AXA1125-003 Top-Line Data
© 2020 Axcella Health Inc. All rights reserved. NASDAQ: AXLA AXA1125 - 003 Top - Line Data May 6, 2020
Slide 2: Forward-looking statements
© 2020 Axcella Health Inc. All rights reserved. 2 This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended, including, without limitation, statements regarding the characteristics, competitive position and develop
Slide 3: About Axcella's Development Model and Clinical Approach
© 2020 Axcella Health Inc. All rights reserved. 3 About Axcella’s Development Model and Clinical Approach EMMs have a fundamental role in biology and function. Using the Axcella Knowledge Base, Axcella designs and develops novel EM M c ompositions to engage identified biologies and pathways. Axcella
Slide 4: AXA1125: A Potential First-Line NASH Therapy
© 2020 Axcella Health Inc. All rights reserved. 4 EMM, Endogenous Metabolic Modulator; FDA, U.S. Food and Drug Administration; NASH, nonalcoholic steatohepatitis. AXA1125: A Potential First - Line NASH Therapy • AXA1125 - 003 findings further validate Axcella’s platform and approach utilizing EMMs •
Slide 5: Axcella's Focus: Endogenous Metabolic Modulators (EMMs)
© 2020 Axcella Health Inc. All rights reserved. 5 Axcella’s Focus: Endogenous Metabolic Modulators (EMMs) EMMs Act as Signaling Agents and Master Regulators in Human Biology • EMMs, including amino acids, are well established agents used to support health • Single EMMs and simple EMM combinations ha
Slide 6: NASH: A Complex Disease with High Unmet Needs
© 2020 Axcella Health Inc. All rights reserved. 6 1. Company estimates based on Decision Resources Group (DRG). Non - alcoholic Steatohepatitis Landscape & Forecast. DRG 2. Cusi , K. Diabetologia . 2016 NASH: A Complex Disease with High Unmet Needs Metabolism Fibrosis Inflammation State of the marke
Slide 7: AXA1125 - A Novel Oral Product Candidate for NASH
© 2020 Axcella Health Inc. All rights reserved. 7 Hypothesized mechanisms depicted above. AAs, amino acids; AMPK, AMP - activated protein kinase; Arg , arginine; Gln , glutamine; GSH, glutathione; Hif1 α, hypoxia - inducible factor 1 alpha; GSH, glutathione; Ile, isoleucine; Leu, leucine; Nac , N -
Slide 8: Positive Results Seen in Previous Clinical Study of AXA1125
© 2020 Axcella Health Inc. All rights reserved. 8 1. Non - IND Clinical Study initiated prior to therapeutic development path decision. Please refer to slide 3 for further detail. 23 subjects received AXA1125 24 g TID and had baseline PDFF >10%; 5 received AXA1125 24 g TID with baseline PDFF <10%; 4
Slide 9: Design of AXA1125-003
© 2020 Axcella Health Inc. All rights reserved. 9 1. Non - IND Clinical Study initiated prior to therapeutic development path decision. Please refer to slide 3 for further detail. 2. C alorie - matched placebo control. BID, 2 times a day; BMx , biomarkers; D, Day; cT1, corrected T1; IND, investigati
Slide 10: Demographics Indicative of a Population with Presumed NASH
© 2020 Axcella Health Inc. All rights reserved. 10 All values are mean (SE) unless otherwise noted. ALT, alanine aminotransferase; AST, alanine transaminase; BMI, body mass index; cT1, corrected T1; HOMA - IR, homeostasis model as sessment of insulin resistance; MRI - PDFF, magnetic resonance imagin
Slide 11: Activity Seen in Subjects Receiving AXA1125 vs. Placebo
11 © 2020 Axcella Health Inc. All rights reserved. Activity Seen in Subjects Receiving AXA1125 vs. Placebo
Slide 12: AXA1125: Reductions Noted in Key Biomarkers
© 2020 Axcella Health Inc. All rights reserved. 12 - 0.7 - 3.4 -6 -4 -2 0 Absolute change, mean (SE), ng/mL - 1.9 - 7.5 -14 -7 0 Relative change, mean (SE), % *p<0.05 versus placebo. ALT, alanine aminotransferase; cT1, corrected T1; FIB - 4, fibrosis 4; HOMA - IR, homeostasis model assessment of ins
Slide 13: AXA1125: Even Greater Activity Seen in Subjects with Diabetes
© 2020 Axcella Health Inc. All rights reserved. 13 - 21.4 - 16.2 -45 -30 -15 0 Relative change, mean (SE), % ALT, alanine aminotransferase; cT1, corrected T1; FIB - 4, fibrosis 4; HOMA - IR, homeostasis model assessment of insulin resistance ; MRI - PDFF, magnetic resonance imaging proton density fa
Slide 14: AXA1125: Insulin and Glucose Changes in Type 2 Diabetes
© 2020 Axcella Health Inc. All rights reserved. 14 HbA1c, glycated hemoglobin; SE, standard error. AXA1125: Insulin and Glucose Changes in Type 2 Subjects with Diabetes Changes from baseline at week 16 - 4.0 - 14.0 -30 -25 -20 -15 -10 -5 0 Absolute change, mean (SE), mIU/L Fasting Insulin - 0.3 - 0.
Slide 15: Activity Seen in Subjects Receiving AXA1125 and AXA1957 vs. Placebo
15 © 2020 Axcella Health Inc. All rights reserved. Activity Seen in Subjects Receiving AXA1125 and AXA1957 vs. Placebo
Slide 16: Greater Metabolism Activity with AXA1125
© 2020 Axcella Health Inc. All rights reserved. 16 HOMA - IR, homeostasis model assessment of insulin resistance; MRI - PDFF, magnetic resonance imaging proton density fat fraction; S E, standard error. Greater Metabolism Activity with AXA1125 Changes from baseline at week 16 Metabolism Placebo AXA1
Slide 17: Greater Impact on Inflammation with AXA1125
© 2020 Axcella Health Inc. All rights reserved. 17 n = 12 26 26 22 25.0 38.5 37.0 31.8 0 10 20 30 40 Subjects, % *p<0.05 versus placebo. ALT, alanine aminotransferase; cT1, corrected T1; SE, standard error . Greater Impact on Inflammation with AXA1125 Changes from baseline at week 16 Inflammation Pl
Slide 18: Equivalent Activity on Fibrosis Markers with AXA1125
© 2020 Axcella Health Inc. All rights reserved. 18 FIB - 4, fibrosis 4; ProC3, propeptide of type III collagen; SE, standard error. Equivalent Activity on Fibrosis Markers with AXA1125 Changes from baseline at week 16 Fibrosis - 0.7 - 3.4 - 4.1 - 3.1 -6 -5 -4 -3 -2 -1 0 Absolute change, mean (SE), n
Slide 19: AXA1125: Meaningful Thresholds of Activity Achieved
© 2020 Axcella Health Inc. All rights reserved. 19 33.0 45.5 0 10 20 30 40 50 Subjects , % 33.0 63.6 0 10 20 30 40 50 60 70 Subjects, % 0.0 54.5 0 20 40 60 Subjects, % 1. Loomba, R. et al. Hepatology. January 2020 2. Loomba, R. et al. Gastroenterology. January 2019 ALT, alanine aminotransferase; cT1
Slide 20: AXA1125 and AXA1957 were Generally Well Tolerated
© 2020 Axcella Health Inc. All rights reserved. 20 1. Safety based on what subject received on day 1 of dosing. Subjects counted only once if they had more than one event repor ted during the product administration period. AE, adverse event; GI, gastrointestinal; SAE, serious adverse event; PEAEs, p
Slide 21: AXA1125: A Potential First-Line NASH Therapy
© 2020 Axcella Health Inc. All rights reserved. 21 EMM, Endogenous Metabolic Modulator; FDA, U.S. Food and Drug Administration; NASH, nonalcoholic steatohepatitis. AXA1125: A Potential First - Line NASH Therapy • AXA1125 - 003 findings further validate Axcella’s platform and approach utilizing EMMs
Slide 22: Multiple Anticipated Milestones in 2020
© 2020 Axcella Health Inc. All rights reserved. 22 AXA1665 and AXA4010 are being investigated in Non - IND Clinical Studies. Please refer to slides 3 for further detail. 1. Timing based on current expectations and subject to risks associated with the COVID - 19 pandemic. 2. We believe that this has
Slide 23: Participating Sites
© 2020 Axcella Health Inc. All rights reserved. Participating Sites: Arizona Liver Health Kansas City Research Institute Chandler & Tucson, AZ Kansas City, MO Bioclinical Research Liver Center of Texas Orlando, FL Dallas, TX Cataline Research Institute National Research Institute Montclair, CA Los A